Repositioning Candidate Details
| Candidate ID: | R0763 |
| Source ID: | DB05301 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | LAX-101 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | LAX-101 treats hungtington’s disease, not just the symptoms but the disease itself. The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical. The molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements. |
| CAS Number: | 909712-41-0 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in depression and huntington's disease. |
| DrugBank Pharmacology: | LAX-101, a novel and proprietary compound that inhibits certain harmful enzymes including phospholipases and caspases, represents a new class of drugs sometimes referred to as NPLs. This class may function as "neuroprotectants" and appears to inhibit degradation of brain tissue by a variety of proposed mechanisms, including stabilization of the phospholipid components of cell membranes and mitochondria, cell structures that are important in cell regulation and brain function. |
| DrugBank MoA: | -- |
| Targets: | Phospholipase D1; Caspase-1 |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|